PCA
GSK icon

Providence Capital Advisors’s GSK GSK Stock Holding History

Providence Capital Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.1K Buy
+1,033
New +$54.6K 0.01% 186
2022
Q3 		– Sell
-3
Closed – – 329
2022
Q2 		$0 Hold
3
– – ﹤0.01% 360
2022
Q1 		$0 Hold
3
– – ﹤0.01% 482
2021
Q4 		$0 Hold
3
– – ﹤0.01% 348
2021
Q3 		$0 Hold
3
– – ﹤0.01% 320
2021
Q2 		$0 Sell
3
-4
-57% -$192 ﹤0.01% 323
2021
Q1 		$0 Sell
7
-36,323
-100% -$1.65M ﹤0.01% 302
2020
Q4 		$1.67M Buy
36,330
+4,563
+14% +$210K 0.68% 50
2020
Q3 		$1.5M Buy
31,767
+1,081
+4% +$54.2K 0.79% 48
2020
Q2 		$1.56M Sell
30,686
-320
-1% -$16.4K 0.89% 47
2020
Q1 		$1.47M Buy
31,006
+1,264
+4% +$67.4K 0.88% 52
2019
Q4 		$1.75M Buy
29,742
+484
+2% +$26.9K 0.94% 47
2019
Q3 		$1.56M Buy
29,258
+287
+1% +$14.8K 0.92% 53
2019
Q2 		$1.45M Buy
28,971
+9,993
+53% +$501K 0.86% 54
2019
Q1 		$991K Buy
18,978
+547
+3% +$27.3K 0.62% 70
2018
Q4 		$880K Buy
18,431
+630
+4% +$31K 0.6% 71
2018
Q3 		$894K Buy
17,801
+247
+1% +$12.5K 0.58% 72
2018
Q2 		$885K Buy
17,554
+361
+2% +$18.2K 0.62% 72
2018
Q1 		$840K Buy
17,193
+1,274
+8% +$59.3K 0.63% 72
2017
Q4 		$706K Buy
+15,919
New +$735K 0.55% 68

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Providence Capital Advisors's GSK Position: Q2 2026 in Review

Providence Capital Advisors opened a new position in GSK (GSK) in Q2 2026: 1,033 shares worth $54.1K. The stake represents 0.01% of the portfolio and ranks #186 among its holdings. This is a return to the name: Providence Capital Advisors previously reported a position in GSK as recently as Q2 2022.

Providence Capital Advisors first reported a position in GSK in Q4 2017 and has held it in 20 quarters since. The position peaked at $1.75M in Q4 2019. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Providence Capital Advisors held 1,033 shares of GSK worth $54.1K as of Q2 2026.
  • GSK was a new Providence Capital Advisors position in Q2 2026.
  • GSK made up 0.01% of Providence Capital Advisors's portfolio in Q2 2026, its #186 holding.
  • Providence Capital Advisors first reported a position in GSK in Q4 2017 and has held it in 20 quarters since.
  • Providence Capital Advisors's GSK position peaked at $1.75M in Q4 2019.
  • 1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Providence Capital Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.